


Remidio with RetinaRisk to strengthen Al-driven diabetic retinopathy screening in India and Iceland

15 April 2025 | News

Partnership will kick off with pilot programmes targeting high-prevalence diabetic populations in India



Bengaluru-based Remidio Innovative Solutions, a global leader in artificial intelligence (AI)-powered ophthalmic diagnostics, has announced a strategic partnership with RetinaRisk, a leading health tech company from Iceland, to enhance risk-based diabetic retinopathy (DR) screening in India and Iceland.

This partnership brings together two powerful innovations, Remidio's Medios DR AI for automated DR detection and RetinaRisk's personalised risk triaging algorithm for progression to sight-threatening DR.

Medios DR is an edge-Al solution that runs entirely on a smartphone without the need for internet access or cloud connectivity, offering real-time DR grading at the point of care. RetinaRisk calculates a patient's risk level and suggests a recommended screening interval using key clinical inputs such as HbA1c, blood pressure, diabetes type and duration, and DR status.

From a public health perspective, this enables more cost-effective DR screening programmes by individualising screening intervals, extending the frequency for low-risk individuals while ensuring timely follow-up for high-risk cases.

The urgency of this collaboration is highlighted by growing global and national public health concerns. Globally, an estimated 22.27% of people with diabetes have diabetic retinopathy, and the number of affected adults is projected to rise from 103.12 million in 2020 to 160.50 million by 2045. India alone accounts for over 9.2 million cases, highlighting the urgent need for scalable, personalized screening models.

The partnership will kick off with pilot programmes targeting high-prevalence diabetic populations in India, aiming to create a scalable framework for prioritised referrals, longitudinal tracking, and reduced vision loss due to DR.